Lexaria Bioscience Corp. (NASDAQ: LEXX) announced today that it has extended its Material Transfer Agreement (MTA) with an undisclosed pharmaceutical company, referred to as PharmaCO, through December 31, 2026. The original MTA, entered into on August 30, 2024, was established to evaluate Lexaria's DehydraTECH technology in a pre-clinical setting for oral drug delivery, specifically targeting GLP-1 receptor agonists, a class of drugs used for diabetes and weight management.
The extension accommodates the time required for PharmaCO to receive and review Lexaria's 2026 research and development results related to GLP-1. Under the extended agreement, the two parties will continue their relationship, maintain the temporary exclusive license, and contemplate additional strategic planning discussions with PharmaCO's human clinical and business development teams. This collaboration underscores the potential of Lexaria's patented DehydraTECH platform to improve oral bioavailability of GLP-1 drugs, which are traditionally administered via injection.
Over the past 12 months, Lexaria has advanced its GLP-1 development program with three key studies: Human Study #7, Animal Study #1, and Animal Study #2. All studies are within the GLP-1 sector and are designed to provide comprehensive evidence to support further collaboration and potential licensing of Lexaria's technology. The studies are fully funded with existing corporate resources, and results are expected during the third and fourth quarters of this calendar year.
DehydraTECH is Lexaria's patented drug delivery formulation and processing platform that enhances the way drugs enter the bloodstream via oral delivery. The technology has repeatedly demonstrated the ability to increase bio-absorption, reduce side effects, and improve drug delivery across the blood-brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
The extension of the MTA is a significant step for Lexaria as it continues to validate its technology with potential partners. The ability to maintain the temporary exclusive license and engage in strategic planning with PharmaCO's clinical and business development teams indicates progress toward potential commercialization. The upcoming results from the three studies will be critical in demonstrating the efficacy of DehydraTECH for GLP-1 drugs, which could open new opportunities in the rapidly growing market for oral alternatives to injectable therapies.
Investors and industry observers will be watching closely for the study results expected later this year, as they could provide further evidence of Lexaria's technology platform and its potential to transform drug delivery for chronic conditions such as obesity and diabetes. The company's focus on GLP-1 aligns with the increasing demand for more patient-friendly oral formulations.
